RUNX1 and acute myeloid leukemia: The 2022 International Consensus Classification (ICC) categorized AML harboring nine sAML-type (secondary AML-type) mutations, including RUNX1, as AML with myelodysplasia-related (MDS-R) gene mutations, which are closely associated with sAML and poorer prognosis [38].